Examples of 'ruxolitinib' in a sentence
Meaning of "ruxolitinib"
Ruxolitinib is a term used in pharmacology to describe a certain type of drug or medication that is possibly used for a specific medical condition
Show more definitions
- A drug used to treat myelofibrosis.
How to use "ruxolitinib" in a sentence
Basic
Advanced
ruxolitinib
The exposure of ruxolitinib active metabolites was unchanged.
Jakavi contains the active substance ruxolitinib.
A causal relationship to ruxolitinib has not been established.
Ruxolitinib is mainly eliminated through metabolism.
There are no human data on the effect of ruxolitinib on fertility.
Effects of ruxolitinib on other medicinal products.
No effects were noted in an evaluation of the neuropharmacological effects of ruxolitinib.
Ruxolitinib was not mutagenic or clastogenic.
Interactions resulting in dose reduction of ruxolitinib.
Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic.
Other interactions to be considered affecting ruxolitinib.
Ruxolitinib is effective in reducing spleen size and alleviating symptoms in a majority of patients.
Haemodialysis is not expected to enhance the elimination of ruxolitinib.
Administration of ruxolitinib to juvenile rats resulted in effects on growth and bone measures.
Jakavi is a medicine that contains the active substance ruxolitinib.
See also
Patients should take Ruxolitinib at the same time every day.
Juvenile rats are more sensitive than adult rats to ruxolitinib toxicity.
It is unknown whether ruxolitinib and / or its metabolites are excreted in human milk.
The active substance of Jakavi is ruxolitinib.
Ruxolitinib decreased foetal weight and increased post-implantation loss in animal studies.
MF patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time.
Ruxolitinib ( Jakavi ) is a kinase inhibitor used to treat certain blood disorders.
Many clinical trials are ongoing involving JAK inhibitors such as ruxolitinib and tofacitinib.
Ruxolitinib trade name Jakafi, and BTK kinase inhibitors.
Nonlimiting exemplary JAK inhibitors include tofacitib and ruxolitinib.
In juvenile rat studies, administration of ruxolitinib resulted in effects on growth and bone measures.
Examples of JAK inhibitors preferably include compounds selected from among Tofacitinib and Ruxolitinib.
In vitro data indicate that ruxolitinib may inhibit P-gp and BCRP.
However, they are responsive to ruxolitinib.
Topical ruxolitinib as a cream applied to vitiligo-affected skin sometimes is effective at repigmenting the skin [ 20 ].
Compound A is also known as ruxolitinib.
Ruxolitinib serves as an inhibitor of JAK 1 and 2.
How can risks of anemia be managed in patients prescribed to ruxolitinib therapy?
Ruxolitinib was not carcinogenic in the Tg . rasH2 transgenic mouse model.
Thus, medicinal products inhibiting these enzymes can give rise to increased ruxolitinib exposure.
The mean elimination half-life of ruxolitinib is approximately 3 hours.
In some embodiments, the additional JAK inhibitor is tofacitinib or ruxolitinib.
Each tablet contains 10 mg ruxolitinib as phosphate.
What Jakavi contains - The active substance of Jakavi is ruxolitinib.
Patients were randomised to the ruxolitinib arm and 112 patients to the BAT arm.
The sum total of all active metabolites contributes to 18 % of the overall pharmacodynamics of ruxolitinib.
Ruxolitinib may inhibit P-glycoprotein and breast cancer resistance protein ( BCRP ) in the intestine.
The frequency of grade 3-4 events was similar for patients treated with ruxolitinib or reference treatments.
Mean ruxolitinib Cmax and total exposure ( AUC ) increased proportionally over a single dose range of 5-200 mg.
All three patients demonstrated “ near-complete hair regrowth ” after three to five months of ruxolitinib treatment.
Ruxolitinib ( Jakavi ) - offered if there is a JAK2 gene mutation.
Therefore, no increase in exposure of CYP3A4 substrates is anticipated when combining them with ruxolitinib.
Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9.
In Janus kinase 2 positive disorders, ruxolitinib ( Jakafi ) can be effective.
E Frequency is based on all patients exposed to ruxolitinib in clinical studies N=4755.
